Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. Company
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo BeiGene, Ltd.
BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).

Number of employees : 5 300 people.
Sales per Business
20192020Delta
Pharmaceutical Products428.21100%308.87100% -27.87%
USD in Million
Sales per region
20192020Delta
China221.5651.7%290.6594.1% +31.18%
United States134.6931.5%18.235.9% -86.47%
Other71.9716.8%---
USD in Million
Managers
Name Title Age Since
John Oyler Chairman & Chief Executive Officer 52 2016
Xiao Bin Wu President & Chief Operating Officer 58 2021
Julia Wang Chief Financial & Accounting Officer 49 2021
Jane Huang Chief Medical Officer-Hematology 47 2016
Yong Ben Chief Medical Officer-Immuno & Oncology Department - 2019
Lai Wang Global Head-Research & Development 43 2021
Christiane Langer Senior Vice President-Global Medical Affairs - 2021
Michael J. Goller Independent Non-Executive Director 45 2015
Donald W. Glazer Independent Non-Executive Director 75 2013
Ranjeev Krishana Independent Non-Executive Director 46 2014
Members of the board
Name Title Age Since
John Oyler Chairman & Chief Executive Officer 52 2016
Michael J. Goller Independent Non-Executive Director 45 2015
Donald W. Glazer Independent Non-Executive Director 75 2013
Ranjeev Krishana Independent Non-Executive Director 46 2014
Qing Qing Yi Independent Non-Executive Director 48 2014
Xiao Dong Wang Non-Executive Director 57 2016
Thomas R. Malley Independent Non-Executive Director 51 2016
Yong Zheng Chen Independent Non-Executive Director 63 2016
Jing Shyh Su Independent Non-Executive Director 67 2018
Anthony C. Hooper Non-Executive Director 65 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0.07692 1,204,567,023 821,244,594 68.2% 0 0.0% 68.2%
Shareholders
NameEquities%
Baker Bros. Advisors LP 11,668,897 12.5%
Capital Research & Management Co. (International Investors) 5,939,650 6.38%
HHLR Advisors Ltd. 5,472,259 5.88%
Fidelity Management & Research Co. LLC 4,250,793 4.57%
Baillie Gifford & Co. 4,249,052 4.57%
PRIMECAP Management Co. 3,857,960 4.15%
Temasek Holdings Pte Ltd. (Investment Management) 2,748,056 2.95%
Invesco Advisers, Inc. 2,317,439 2.49%
Capital Research & Management Co. (Global Investors) 1,828,239 1.96%
Capital Research & Management Co. (World Investors) 1,828,239 1.96%
Holdings
NameEquities%Valuation
LEAP THERAPEUTICS, INC. (LPTX) 7,348,437 8.42% 29,467,232 USD
Company contact information
BeiGene Ltd.
Zhongguancun Life Science Park
No. 30 Science Park Road
Changping District
Beijing 102206

Phone : +86.10.58958000
Fax : +86.10.58958080
Web : http://www.beigene.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of BeiGene, Ltd.